Apellis Pharmaceuticals, Inc. · NASDAQ:APLS
Apellis Pharmaceuticals — Q2 2023 Earnings Presentation
12 slides from Apellis Pharmaceuticals's earnings presentation, Jul 31, 2023
Slide 1: Second Quarter 2023 Financial Results Conference Call
Second Quarter 2023 Financial Results Conference Call July 31, 2023
Slide 2: Apellis Participants
Apellis Participants CEDRIC FRANCOIS, M.D., Ph.D. Co-Founder, President & Chief Executive Officer ADAM TOWNSEND Chief Commercial Officer CAROLINE BAUMAL, M.D. Chief Medical Officer T I M O T H Y S U L L I VA N Chief Financial Officer 2 APELLIS PROPRIETARY INFORMATION / FOR APELLIS USE ONLY
Slide 3: Forward-looking statements
Forward-looking statements Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act
Slide 4: Patient safety is our top priority
Patient safety is our top priority
Slide 5: Safety events in real world vs. clinical trials
Safety events in real world vs. clinical trials We believe the safety events in the real world have been very rare Thousands of vials • >68,000 vials of SYFOVRE distributed since launch distributed Rare • Seven confirmed reports of retinal vasculitis in real world events • One reported event being e
Slide 6: No indication that drug product or manufacturing issues contributed to the safety events
No indication that drug product or manufacturing issues contributed to the safety events Assessed manufacturing processes and drug product quality and found: • No single manufacturing lot implicated • No manufacturing issues impacting product quality identified • No quality issues • No contaminants
Slide 7: Recent learnings from market research
Recent learnings from market research Among N=41 surveyed retina specialists who use SYFOVRE: 1 plan to continue using SYFOVRE as they had been prior to the vasculitis events 3 (new and treated patients) 1 3 plan to continue using SYFOVRE on treated patients 1 plan to pause until more information is
Slide 8: Consolidated Second Quarter 2023 Financial Results
Consolidated Second Quarter 2023 Financial Results (In USD Millions) Three Months Ended June 30, 2023 2022 EMPAVELI U.S. Net Product Sales $22.3 $15.7 SYFOVRE U.S. Net Product Sales $67.3 -- Licensing and Other Revenue $5.3 $0.6 Total Revenue $95.0 $16.3 Cost of Sales $8.4 $0.1 Expenses R&D Expenses
Slide 9: SYFOVRE continues to show increasing effects over time in GALE long term extension study
SYFOVRE continues to show increasing effects over time in GALE long term extension study 5.5 Reduction vs sham 39% 32% 5.0 PM: 24%; p<0.0001 GA lesion change from baseline 4.5 PEOM: 21%; p<0.0001 32% 27% 4.0 LS mean (SE), mm² Presented at ASRS 3.5 17% 18% 3.0 2.5 19% 17% 2.0 1.5 13% 14% Pegcetacopla
Slide 10: GALE: Reductions in GA Lesion Growth in Patients With Nonsubfoveal Lesions
GALE: Reductions in GA Lesion Growth Following 30 Months of Continuous Treatment With Pegcetacoplan in Patients With Nonsubfoveal Lesions 7.0 Reduction vs sham 45% 33% 6.5 PM: 31%; p<0.0001 GA lesion change from baseline 6.0 PEOM: 26%; p<0.0001 30% 28% 5.5 5.0 LS mean (SE), mm² Presented at ASRS 4.5
Slide 11: SYFOVRE protects photoreceptor cell degeneration
SYFOVRE protects photoreceptor cell degeneration Sham pooled to pegcetacoplan treatment Crossover to pegcetacoplan 5.0 Photoreceptor degeneration per total FOV -106.0% difference (p<0.0001) LS mean change per Presented at ASRS 4.5 LS mean (SE) CFB, mm² 6 months 4.0 3.5 Sham pooled Pegcetacoplan pool
Slide 12: Second Quarter 2023 Financial Results Conference Call
Second Quarter 2023 Financial Results Conference Call July 31, 2023
Apellis Pharmaceuticals — Q2 2023 Earnings Presentation on 6ix